JP Morgan Maintains Neutral on Moderna, Lowers Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains a Neutral rating on Moderna (NASDAQ:MRNA) but lowers the price target from $96 to $88.
August 15, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan analyst Jessica Fye maintains a Neutral rating on Moderna but lowers the price target from $96 to $88.
The lowered price target from $96 to $88 by JP Morgan suggests a less optimistic outlook for Moderna's stock performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100